Randomized Comparison of Contrast Agents Gadopiclenol and Gadobutrol in the Workup of Incidental Renal and Adrenal Findings
Recruiting now · Phase 4
Conditions studied: Suspect Renal and Adrenal Imaging Findings
In brief
The purpose of this study is to compare the effects of the contrast agent Gadopiclenol with those of the standard contrast agent Gadobutrol. The main question of this study is : Does gadopiclenol offer diagnostic properties that are equally effective as those of gadobutrol? Participants will be: * randomly assigned to one of two groups: the experimental group, which receives gadopiclenol, or the control group, which receives gadobutrol. Each participant is informed of their group allocation prior to the magnetic resonance imaging (MRI) scan. * invited for a single MRI appointment lasting approximately 60 minutes
Key facts
- Study ID
- NCT07040865
- Run by
- Insel Gruppe AG, University Hospital Bern
- People needed
- 104
- Starts
- 2025-08-18
- Expected to finish
- 2027-07-31
- Last updated by the study team
- 2025-11-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- signed informed consent
- age ≥18 years
- compatibility with magnetic resonance imaging
- planned workup of kidney incidental finding or adrenal incidental findings (or both)
- body mass index (BMI) < 31 kg/m2
You may not qualify if…
- patients with implants that might affect imaging parameters in the region under investigation, as judged by the principal investigator
- vulnerable individuals
- claustrophobic individuals
- individuals that are cognitively impaired or unable to understand the language
- pregnant or breastfeeding patients
Where it is running
- Department of Diagnostic, Interventional and Pediatric Radiology Inselspital, University of Bern — Bern, Switzerland (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.